Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of CancerPRNewsWire • 09/13/24
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/05/24
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current FundamentalsSeeking Alpha • 08/14/24
Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical LevelInvestors Business Daily • 08/07/24
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/06/24
How These Two Lesser-Known Biotech Names Obliterated Sales ExpectationsInvestors Business Daily • 08/06/24
Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 08/05/24
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your SkinInvestors Business Daily • 07/03/24
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple SclerosisPRNewsWire • 06/25/24